tradingkey.logo

Citi says Lupin-Astellas settlement may delay rival generic launches

ReutersFeb 10, 2026 6:13 AM

Citi Research says Lupin's LUPN.NS $90 million patent settlement with Astellas Pharma 4503.T may prevent other generic drugmakers from launching generic Mirabegron for an extended period, potentially giving Lupin and Zydus Lifesciences ZYDU.NS about 12–18 months of limited competition

Settlement allows Lupin to continue selling its generic version of Mirabegron, a bladder disorder drug, eliminating legal risks associated with prolonged litigation - Citi

Citi maintains "buy" on LUPN at PT 2260 rupees

Stock rated "buy" on avg by 35 analysts; median PT 2350 rupees - data compiled by LSEG

Stock up 5% YTD; last up 1% at 2218 rupees

Disclaimer: The information provided on this website is for educational and informational purposes only and should not be considered financial or investment advice.

Related Articles

KeyAI